Corporate Profile

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx™ Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of diseases areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Stock Quote

  • Change
  • Volume
  • Today's Open
  • Previous Close
  • Today's High
  • Today's Low
  • 52 Week High
  • 52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.